Gyre Therapeutics, Inc. (GYRE) Reports Q2 EPS of $0.01

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. ARM
3. FIS
4. BROS
5. QCOM
6. EXPE
7. FSLY
8. CPAY
9. FICO
10. PAYC

Go back to Gyre Therapeutics, Inc. (GYRE) Reports Q2 EPS of $0.01

Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update

August 13, 2024 6:00 AM EDT

Received NMPA approval of avatrombopag maleate tablets for the treatment of CLD-associated thrombocytopenia, expanding rare disease product lines

Received IND approval from NMPA to evaluate F230 for the treatment of pulmonary arterial hypertension

U.S. IND submission for F351 in MASH-associated liver fibrosis expected in late 2024 and data readout from Phase 3 trial in CHB-associated liver fibrosis in the PRC expected by early 2025

Cash and cash equivalents totaled $16.1 million as of June 30, 2024

SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (Gyre) (Nasdaq:... More